CM336 for Autoimmune Blistering Disease
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This study tests a new drug called CM336 for people with autoimmune blistering diseases. The drug is designed to calm the immune system and reduce blistering, aiming to improve skin health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of an autoimmune blistering disease (like pemphigus or bullous pemphigoid).
- You are 18 years old or older.
- You have not been treated with a drug that targets BCMA (a protein on immune cells).
- You are not allergic to monoclonal antibody drugs or any ingredient in the study drug CM336.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called CM336 for people whose immune system mistakenly attacks their own blood cells (autoimmune cytopenia) and hasn't been controlled by other treatments. The goal is to see if CM336 can safely help improve blood cell counts.
This trial tests a new treatment called OM336 for people with active autoimmune diseases that have not improved after at least two other treatments. The goal is to see if OM336 can help control the disease.
This study tests a new medicine called CM313 for people with moderate to severe pemphigus, a condition that causes painful blisters on the skin and mouth. The goal is to see if CM313 can help reduce these blisters and improve quality of life.
This study tests a new drug called CM313 (an antibody that targets a protein on immune cells) for treating pemphigus, a condition that causes painful blisters on the skin and mouth. The goal is to see if it can reduce blisters and improve quality of life, especially for people who haven't responded well to other treatments.
This trial tests a new drug called OM336 for people whose immune system is attacking their own blood cells, causing low counts. It is for those who have already tried at least one treatment that did not work well or stopped working.
This trial tests a new drug called CM336 for people with immune thrombocytopenia (ITP) that hasn't responded well to other treatments. It aims to see if CM336 can safely help raise platelet counts and reduce bleeding risk.
Hear when a new Autoimmune Bullous Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.